ClinicalTrials.gg
RecruitingNCT04899583Updated Nov 29, 2023

ACOART SCB BIF: Treatment of Coronary Bifurcation Lesion by Sirolimus Coated Balloon vs Paclitaxel Coated Balloon

An interventional study of Sirolimus Coated Balloon Catheter and a Paclitaxel Coated Balloon Catheter in Coronary Bifurcation Lesions, sponsored by Acotec Scientific Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Acotec Scientific Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The aim of this randomized controlled trial is to examine the treatment of coronary bifurcation lesion with a sirolimus coated balloon versus a paclitaxel coated balloon. This trial is designed as prospective, multicenter, randomized and open-label.

02

Conditions studied

  • Coronary Bifurcation Lesions
03

In context

Lead sponsor

Acotec Scientific Co., Ltd is the lead sponsor of 17 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old and ≤75 years old
  • Diagnosed as stable or unstable angina pectoris, asymptomatic myocardial ischemia or old myocardial infarction, or recent myocardial infarction in stable stage.
  • Eligible for balloon dilatation or stent implantation.
  • Subject (or legal guardian) understands the study requirements and procedures and provides written before any study tests or procedures are performed

Exclusion criteria

Exclusion Criteria:

  • AMI occurred within 7 days before operation
  • The subjects had congestive heart failure or the heart function was classified as /KillipIV.
  • (LVEF) \< 35%
  • History of heart transplantation
  • The subjects had severe arrhythmias, such as high-risk ventricular extrasystole and / or ventricular tachycardia.
  • The subjects had stroke, gastrointestinal bleeding or active ulcers, or had a high risk of bleeding in the past 6 months.
  • Active bleeding physique or blood coagulation disorder
  • Known renal insufficiency(\<30ml/min)
  • to anticoagulants or antiplatelet agents
  • Has a history of percutaneous coronary intervention (PCI) within 6 months before enrollment.
  • Has contraindications for coronary artery bypass grafting
  • known to be allergic to aspirin, heparin, contrast agents, paclitaxel and sirolimus
  • less than 12 months, or unable to complete a 12-month follow-up
  • Pregnant or lactating females, or who plan to become pregnant during a follow-up period of 1 year after operation
  • The subjects have participated in other drug property studies or device studies that have not yet completed the main end point.

Angiographic Inclusion Criteria:

  • One target lesion (bifurcation lesion) in the coronary artery is allowed, and if there are coexistent non-bifurcated lesions requiring PCI intervention, only one lesion was accepted at most, and the target lesion should be treated after successful PCI treatment of non-target lesion.
  • Target Lesion located in native coronary artery must be de novo
  • Medina classification should be (1.1.1, 1.0.1, 0.1.1)
  • Main branch of target lesion (%DS is ≥70% or ≥50% with clinical symptoms ) is suitable for stent implantation
  • Target Lesion located in main branch should be covered by DES. Moreover, the residual stenosis ≤ 30%, TIMI flow is 3, no complications and branch vessel opening stenosis ≥ 70%.
  • Reference vessel diameter of the branch is 2.0-4.0mm (by visual)
  • Target lesion length ≤ 36mm (by visual)

Angiographic Exclusion Criteria:

  • Target or non-target lesion located in left main
  • Subjects who have non-target lesions of bifurcation
  • The target lesion is trifurcation or multifurcation lesion.
  • Main branch of target lesion located within 3 mm from the ostium of LAD or LCx or RCA
  • The branch lesion is a diffuse long lesion, which could't covered by one DCB.
  • Main or side branch is occlusive lesion, which TIMI flow is 0.
  • Aneurysm existed in the blood vessel at the target lesion
  • Side branch severely calcified or tortuous
  • The blood pressure was too low to tolerate intracoronary injection of ≥ 100ug nitroglycerin
  • Failure pre-dilatation of the side branch ostium (residual stenosis > 30% ,the blood flow in TIMI is not up to grade 3, or has dissection of type C or above according to NHLBI grade)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    a Sirolimus Coated Balloon

    Device: Sirolimus Coated Balloon Catheter

  • Active comparator
    Control Group

    a Paclitaxel Coated Balloon Catheter

    Device: a Paclitaxel Coated Balloon Catheter

Interventions

  • DeviceSirolimus Coated Balloon Catheter

    a Sirolimus Coated Balloon Catheter designed and produced by Acotec

  • Devicea Paclitaxel Coated Balloon Catheter

    a Paclitaxel Coated Balloon Catheter(trade name:Bingo)

06

What researchers measure

Primary outcomes

  1. Diameter stenosis rate of bifurcation lesion determinated by Digital Substraction Angiography (DSA) at 9 months post procedure.

    Defined as (1-minimum lumen diameter of target lesion/reference vessel diameter)\*100% at 9 months post procedure.

    Time frame: 9 months post procedure

Secondary outcomes

  1. Rate of device success

    Defined as the rate of successful delivery and withdrawal of the delivery catheter, and achieving a final in-lesion residual stenosis less than 30% and TIMI flow grade 3 by using the assigned device only.

    Time frame: Immediately after procedure

  2. Rate of lesion success

    Defined as the rate of achieving a final in-lesion residual stenosis \< 30% by visual estimate and TIMI flow grade 3 by using any percutaneous method.

    Time frame: Immediately after procedure

  3. Rate of procedure success

    Defined as the rate of achieving lesion success without MACE (composite of cardiac death, MI and TLR events) .

    Time frame: Immediately after procedure

  4. Rate of target lesion failure (TLF) or device-related composite endpoints (DoCE)

    Defined as a composite rate of cardiac death, target vessel-related MI, or ischemia-driven TLR events at 30 days, 6 months, 9 months and 12 months post procedure.

    Time frame: 30 days, 6 months, 9 months, 12 months post procedure

  5. Rate of patient-related composite endpoints (PoCE)

    Defined as a composite rate of all cause death, all cause-related MI or TLR events at 30 days, 6 months, 9 months and 12 months post procedure.

    Time frame: 30 days, 6 months, 9 months, 12 months post procedure

  6. Diameter stenosis rate

    Defined as the rate of restenosis (\>50% diameter stenosis) of main vessel after 9 months at 9 months post procedure.

    Time frame: 9 months post procedure

  7. Late lumen loss (LLL)

    Defined as the difference of minimum lumen diameter (MLD) from post procedure to 9 months follow-up, including late lumen loss of main vessel and side branch.

    Time frame: 9 months post procedure

  8. Angiographic binary restenosis (ABR) rate

    Defined as the percentage rate of binary restenosis determined by angiographic at 9 months post procedure.

    Time frame: 9 months post procedure

  9. Rate of composite safety endpoint

    Defined as a composite rate of all-cause death, cardiogenic death, myocardial infarction, target vessel-related myocardial infarction, incidence of thrombotic events (acute, subacute, late) defined by ARC at 12 months post procedure.

    Time frame: 12 months post procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Nov 2024, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2021
First posted
May 24, 2021
StartActual
Nov 10, 2021
Primary completionEst.
Nov 1, 2024
CompletionEst.
Nov 1, 2025
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04899583
Lead sponsor
Acotec Scientific Co., Ltd
Responsible party
Sponsor
First posted
May 24, 2021
Start date
Nov 10, 2021
Primary completion
Nov 1, 2024 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
Nov 29, 2023

Study contacts

Lu Hao
Contact
lu.hao.@zs-hospital.sh.cn
021-64041990
Ge Junbo
principal investigator · Shanghai Zhongshan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion